Parth Shah1. 1. ObvioHealth, 3452 Lake Lynda Dr., Building 100, Suite 151, Orlando, FL, 32817, USA. prshah06@gmail.com.
Abstract
PURPOSE OF REVIEW: This review aims to explore and summarize the current literature on the cardiovascular disease (CVD) healthcare burden and determine the cost-effectiveness of the PCSK9 inhibitors. RECENT FINDINGS: The CVD remain the largest cause of mortality in the USA presenting substantial healthcare cost burden reaching $555 billion in 2016 and projected to rise to $1.1 trillion by 2035. The PCSK9 inhibitors have shown strong efficacy in LDLC lowering, but its price of ~ 14,000-14,600 per patient per year coupled with ~ 2.2-2.8 years of cardiovascular outcome data has created many controversies surrounding its cost-effectiveness. To determine the cost-effectiveness of the PCSK9 inhibitors, various simulation models and risk-based stratification and case-by-case patient approachs have yielded divisive data which need to be reassessed as per the ODYSSEY and long-term CVD outcomes. Further studies are warranted to evaluate the long-term CVD event rates of patients on the PCSK9 inhibitors to determine its true cost-effectiveness.
PURPOSE OF REVIEW: This review aims to explore and summarize the current literature on the cardiovascular disease (CVD) healthcare burden and determine the cost-effectiveness of the PCSK9 inhibitors. RECENT FINDINGS: The CVD remain the largest cause of mortality in the USA presenting substantial healthcare cost burden reaching $555 billion in 2016 and projected to rise to $1.1 trillion by 2035. The PCSK9 inhibitors have shown strong efficacy in LDLC lowering, but its price of ~ 14,000-14,600 per patient per year coupled with ~ 2.2-2.8 years of cardiovascular outcome data has created many controversies surrounding its cost-effectiveness. To determine the cost-effectiveness of the PCSK9 inhibitors, various simulation models and risk-based stratification and case-by-case patient approachs have yielded divisive data which need to be reassessed as per the ODYSSEY and long-term CVD outcomes. Further studies are warranted to evaluate the long-term CVD event rates of patients on the PCSK9 inhibitors to determine its true cost-effectiveness.
Authors: William S Weintraub; Stephen R Daniels; Lora E Burke; Barry A Franklin; David C Goff; Laura L Hayman; Donald Lloyd-Jones; Dilip K Pandey; Eduardo J Sanchez; Andrea Parsons Schram; Laurie P Whitsel Journal: Circulation Date: 2011-07-25 Impact factor: 29.690
Authors: Dhruv S Kazi; Andrew E Moran; Pamela G Coxson; Joanne Penko; Daniel A Ollendorf; Steven D Pearson; Jeffrey A Tice; David Guzman; Kirsten Bibbins-Domingo Journal: JAMA Date: 2016-08-16 Impact factor: 56.272
Authors: Michael J Koren; Marc S Sabatine; Robert P Giugliano; Gisle Langslet; Stephen D Wiviott; Helina Kassahun; Andrea Ruzza; Yuhui Ma; Ransi Somaratne; Frederick J Raal Journal: JAMA Cardiol Date: 2017-06-01 Impact factor: 14.676
Authors: Kausik K Ray; Henry N Ginsberg; Michael H Davidson; Robert Pordy; Laurence Bessac; Pascal Minini; Robert H Eckel; Christopher P Cannon Journal: Circulation Date: 2016-10-24 Impact factor: 29.690